Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification

Non-small Cell Lung Cancer Clinical Trial

— SACHI  

Official title:

Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Savolitinib + Osimertinib Versus Pemetrexed + Platinum in Treatment of Patients With NSCLC With MET Amplification

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05015608
• Other study ID #: 2020-504-00CH3
• Status: Recruiting
• Phase: Phase 3
• Start date: November 22, 2021
• Est. completion date: November 30, 2024

Study information

• Verified date: March 2023
• Source: Hutchmed
• Contact: Lu Chen
• Phone: +86 21 20673000
• Email: Luc[@]hutch-med.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will look at how effective the study drug(Savolitinib combined with Osimertinib) versus Pemetrexed combined with platinum in treatment of patients with locally advanced or metastatic NSCLC with MET amplification after failure of the first-line EGFR inhibitor therapy.

Description:

This is a multicenter, randomized, controlled, open, phase III clinical study to evaluate the clinical efficacy and safety of Savolitinib combined with Osimertinib in treatment of patients with locally advanced or metastatic NSCLC with MET amplification after failure of EGFR inhibitor therapy.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 250
• Est. completion date: November 30, 2024
• Est. primary completion date: September 15, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Fully aware this study and voluntary to sign the informed consent form, and willing and able to comply with the study procedure;

2. Age = 18 and =75 years;

3. In accordance with the 8th Edition of TNM staging for lung cancers by International Association for the Study of Lung Cancer and American Joint Committee on Cancer, patients with histologically or cytologically confirmed unresectable and non-suitable for radical concurrent chemoradiotherapy, locally advanced or metastatic (stage IIIB, IIIC or IV) NSCLC;

4. EGFR sensitive mutations prior to the first-line EGFR-TKI therapy;

5. Radiologically documented disease progression after the first-line EGFR-TKI;

6. MET amplification after disease progression following the first-line therapy;

7. Having measurable lesions (in accordance with RECIST 1. 1 criteria);

8. United States Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1;

9. Expected survival >12 weeks;

10. Adequate bone marrow reserve or organ function

11. Female patients of childbearing potential must agree to use effective contraceptive methods from screening period to 4 weeks after discontinuation of the study drug;

12. Male subjects should be willing to agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agreement to refrain from donating sperm. ;

13. Being able to take or swallow the drug orally.

Exclusion Criteria:

1. Patients with positive T790M mutations;

2. Previous treatment for c-MET;

3. Currently having other malignant tumors, or having other infiltrating malignant tumors in the past 5 years.;

4. Previous use of systematic antitumor therapy other than EGFR-TKI for advanced NSCLC;

5. Currently having received antiangiogenic therapy or traditional Chinese medicine with antitumor indication?extensive radiotherapy ?palliative local radiotherapy, a major surgery,or participated in other drug clinical trials and received corresponding tudy drug etc;

6. Currently receiving the potent CYP3A4 inducers or potent CYP1A2 inhibitors within two weeks prior to the start of study treatment;

7. Having not been sufficiently recovered from the toxicity and/or complication resulting from any interventional measure prior to the start of treatment;

8. Clinically significant active infection, including but not limited to tuberculosis, human immunodeficiency virus (HIV) infection (positive HIV1/2 antibody);

9. Active hepatitis B, or active hepatitis C;

10. Acute myocardial infarction, unstable angina pectoris, stroke or transient ischemic attack;

11. Known cancerous thrombus or deep vein thrombosis or uncontrollable hypertension despite the use of drugs;

12. Mean resting corrected QT interval (QTcF) or Any important abnormality in rhythm;

13. Presence of meningeal metastases, spinal cord compression or active brain metastases prior to the start of study treatment;

14. Active gastrointestinal disease or other conditions significantly affecting the absorption, distribution, metabolism or excretion of oral study drug;

15. Lack of compliance with participation in this clinical study or inability to comply with the limitations and requirements of the study, as judged by investigators;

16. Known allergy to the active or inactive ingredient of Savolitinib or Osimertinib;

17. Previous history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis and any active interstitial lung disease;

18. Pregnant or breastfeeding women;

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Non-small Cell Lung Cancer

Intervention

Drug:
• Savolitinib + Osimertinib
Subjects will receive Savolitinib orally once per day (QD) + Osimertinib orally QD,21day cycles (every 3 weeks) until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.
• Pemetrexed + Cisplatin /Carboplatin
Pemetrexed combined with platinumon on Day 1 of 21day cycles (every 3 weeks)

Locations

Country	Name	City	State
China	Shanghai Chest Hospital	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Hutchison Medipharma Limited

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	PFS	Progression-free survival (PFS) using Investigator assessment as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).	5 months after the last patient enrolled
Secondary	Safety and tolerability	Incidence and nature of treatment emergent adverse events (TEAE), the other safety variables including physical examination, vital signs and laboratory examinations	5 months after the last patient enrolled
Secondary	The objective response rate of the tumor (ORR)	the incidence of confirmed complete response or partial response	5 months after the last patient enrolled
Secondary	The disease control rate (DCR)	the incidence of complete response, partial response and stable disease	5 months after the last patient enrolled
Secondary	Duration of Response (DoR)	the duration between the date the criteria for complete response or partial response was first measured (first record shall prevail) and the date of disease recurrence or progression as objectively recorded	5 months after the last patient enrolled
Secondary	Overall survival (OS)	the time from the date of randomization to the date of death (all causes)	5 months after the last patient enrolled
Secondary	Time to Response (TTR)	the period from the date of randomization to the date when the criteria for complete response or partial response was first measured (first record shall prevail).	5 months after the last patient enrolled
Secondary	PFS	Progression-free survival (PFS) using IRC as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)	5 months after the last patient enrolled